Literature DB >> 10583061

Pneumocystis carinii pneumonia in patients receiving immunosuppressive drugs for dermatological diseases.

S P Raychaudhuri1, S Siu.   

Abstract

In recent years, Pneumocystis carinii pneumonia (PCP) has been increasingly reported in patients without human immunodeficiency virus (HIV) infection. The increased occurrence of PCP in non-HIV-immunocompromised subjects has been attributed to several factors: use of stronger immunosuppressive regimens, higher awareness of PCP, advanced diagnostic technology and nosocomial spread of P. carinii. Appearance of PCP subsequent to the use of immunosuppressive drugs has been noticed in many inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus and ulcerative colitis. Dermatologists frequently use immunomodulating agents, but the occurrence of PCP in patients receiving immunosuppressive drugs for skin diseases is largely unknown. We report four cases where PCP appeared following the use of immunosuppressive drugs primarily for cutaneous diseases, namely pemphigus, cutaneous necrotizing vasculitis (two cases) and Behçet's syndrome. These cases were identified in a computerized database study (1979-95) to evaluate the occurrence of PCP among immunocompromised hosts without HIV infection.

Entities:  

Mesh:

Year:  1999        PMID: 10583061     DOI: 10.1046/j.1365-2133.1999.03052.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

Review 1.  Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients.

Authors:  Anat Stern; Hefziba Green; Mical Paul; Liat Vidal; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2014-10-01

2.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

3.  Risk Factors for Mortality in Pneumocystis jirovecii Pneumonia in Patients with Inflammatory Bowel Disease.

Authors:  Atsushi Yoshida; Noriko Kamata; Akihiro Yamada; Yoko Yokoyama; Teppei Omori; Toshimitsu Fujii; Ryohei Hayashi; Tetsu Kinjo; Akira Matsui; Norimasa Fukata; Sakuma Takahashi; Ryosuke Sakemi; Noriyuki Ogata; Shinya Ashizuka; Shigeki Bamba; Makoto Ooi; Shuji Kanmura; Katsuya Endo; Takuya Yoshino; Hiroki Tanaka; Toshio Morizane; Shinichiro Shinzaki; Taku Kobayashi
Journal:  Inflamm Intest Dis       Date:  2019-02-06

Review 4.  Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention.

Authors:  Evin Sowden; Andrew J Carmichael
Journal:  BMC Infect Dis       Date:  2004-10-16       Impact factor: 3.090

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.